Literature DB >> 7200369

Leukaemia of platelet precursors: diverse features in four cases.

D Bevan, M Rose, M Greaves.   

Abstract

Four patients are described with malignant cells of definite or probable megakaryocytic lineage in the bone marrow and blood. Megakaryocytic features were defined by morphological and cytochemical studies using light and electron microscopy, and in two cases by reaction with a monoclonal anti-platelet antibody, AN51. All patients had increased bone-marrow reticulin, which developed in less than 15 months in two cases. One of these fitted the clinical pattern of acute myelosclerosis of Lewis and Szur (now widely referred to as acute megakaryoblastic leukaemia). Three cases had unique clinical features which are described in detail. There may be several variants of megakaryocytic leukaemia, including chronic forms. One variant is associated with Down's syndrome (trisomy 21).

Entities:  

Mesh:

Year:  1982        PMID: 7200369     DOI: 10.1111/j.1365-2141.1982.tb07299.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Treatment of dysmyelopoietic/leukemic syndromes with myelofibrosis and megakaryocytic hyperplasia with large doses of cytosine arabinoside.

Authors:  H D Preisler; A Raza; M Barcos
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

Review 2.  Myeloid leukemia in Down syndrome.

Authors:  Irum Khan; Sébastien Malinge; John Crispino
Journal:  Crit Rev Oncog       Date:  2011

3.  Leukaemia and transient leukaemia in Down syndrome.

Authors:  L Iselius; P Jacobs; N Morton
Journal:  Hum Genet       Date:  1990-10       Impact factor: 4.132

4.  Down syndrome and leukemia: unusual clinical aspects and unexpected methotrexate sensitivity.

Authors:  M Peeters; A Poon
Journal:  Eur J Pediatr       Date:  1987-07       Impact factor: 3.183

5.  Human megakaryocytes. V. Changes in the phenotypic profile of differentiating megakaryocytes.

Authors:  R B Levene; J M Lamaziere; H E Broxmeyer; L Lu; E M Rabellino
Journal:  J Exp Med       Date:  1985-03-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.